Subhajit Biswas & Soumi Sukla (2020). COVID-19 Virus Infection and Transmission are Observably Less in Highly Dengue-endemic Countries: Can Dengue Vaccines be “Repurposed” to Prevent COVID-19? (https://www.prepri nts.org/manuscript/202004.0040/v3)
Nath H#, Mallick A#, Roy S, Sukla S, Biswas S*(2020). Computational modelling predicts that Dengue virus antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity? (https://doi.org/10.31219/osf.io/dutx4)
Himadri Nath#, Abinash Mallick#, Subrata Roy, Soumi Sukla, Keya Basu, Abhishek De, Subhajit Biswas* (2020). Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist. (https://www.medrxiv.org/content/10.1101/2020.07.03.20145797v1.article-metrics) Important Citation: Our first report (globally) (6th July 2020; medRxiv; item 9 above) that archived Dengue serum samples from 2017 cross-reacted in COVID-19 lateral flow-based strip tests has been cited in "National Guidelines for Dengue Case Management during COVID-19 pandemic" by the Ministry of Health & Family Welfare, Govt. of India. Please see page number 13 and 31 of the Report. https://nvbdcp.gov.in/Doc/National%20Guideline%20for%20Dengue%20case%20management%20during%20COVID-19%20pandemic.pdf